Gambro subpoenaed on PTH testing
This article was originally published in The Gray Sheet
Despite receipt of a Nov. 5 DoJ subpoena seeking documentation on parathyroid hormone testing, Gambro remains on-track to finalize by year-end a July preliminary settlement agreement with the U.S. Department of Justice related to renal care Medicare billing practices initially cited in a June 2001 subpoena, the firm says (1"The Gray Sheet" July 26, 2004, p. 13). Similar subpoenas on PTH testing were received the week of Oct. 25 by several other dialysis-related product and service providers as part of an industry-wide investigation aimed at increasing DoJ's understanding of PTH testing and vitamin D therapy (2"The Gray Sheet" Nov. 1, 2004, In Brief). PTH testing represents about 1% of total U.S. Gambro Healthcare revenue...
You may also be interested in...
Gambro Healthcare US will record a second quarter charge of $355 mil. to cover a definitive settlement agreement with the U.S. Department of Justice, expected to be completed by December
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.